InvestSMART
  1. Home
  2. Research & Advice
  3. Research Tools
  4. Shares
  5. No research was found for CURE but you can find our latest research below...
  6. Research

Global X S&P Biotech ETF (ASX: CURE) - Related Research

Current share price for CURE : $43.000 0.76 (1.80%)+

Global X S&P Biotech ETF (CURE) is an Exchange Traded Fund - commonly known as an ETF. For more details about how ETFs work, feel free to check out our What is an ETF? overview. The Global X S&P Biotech ETF (CURE) seeks to invest in companies that stand to benefit from further advances in the field of genomic science, such as companies involved in gene editing, genomic sequencing, genetic medicine/therapy, computational genomics, and biotechnology.

No research was found for CURE but you can find our latest research below...

Boring into Orora

Newly spun out of Amcor, Orora is a desperately dull business but that, explains Gaurav Sodhi, is what gets us excited.

Gaurav Sodhi

06 Feb 2014
·
Article comments

AWE on sale

The disposal of part of its stake in the BassGas project sheds light on AWE's value and shows our investment case remains on track.

Gaurav Sodhi

03 Feb 2014
·
Article comments

M2 takes a breather

After a period of rapid expansion, Jason Prowd explains why this ‘corporate pause’ is exactly what’s needed at this junior telco.

Jason Prowd

29 Jan 2014
·
Article comments

4301 - 4325 of 14802 results

Page 173 of 593

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.